Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
77 participants
OBSERVATIONAL
2022-11-10
2023-03-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Research on the Accurate Diagnosis of Urinary Tract Tumors and the Development of Kits
NCT06193941
Establishment and Validation of an Early Diagnostic Model for Bladder Cancer Based on Serum and Urine Metabolomics
NCT04966962
Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder
NCT02745301
A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing
NCT07036731
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
NCT02379429
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with confirmed bladder tumor
Patients with bladder tumor, confirmed by cystoscopy and radiology. Age ranging from 18 to 80 years old. Women of childbearing age should have negative urine pregnancy test.
analysis of urine volatile organic compounds
gas chromatography - mass spectrometry will be used to assess the composition of VOCs in urine samples of all participants.
Healthy volunteers
Individuals with no known disease and normal urinalysis. Age ranging from 18 to 80 years old. Women of childbearing age should have negative urine pregnancy test.
analysis of urine volatile organic compounds
gas chromatography - mass spectrometry will be used to assess the composition of VOCs in urine samples of all participants.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
analysis of urine volatile organic compounds
gas chromatography - mass spectrometry will be used to assess the composition of VOCs in urine samples of all participants.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* women of childbearing age with negative urine pregnancy test result
* willing to participate in this trial and sign the informed consent form
Exclusion Criteria
* patient involved in other clinical trials
* other situations researcher considered to be ineligible for this trial
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital Xi'an Jiaotong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jinhai Fan, MD
Role: STUDY_DIRECTOR
First affiliated hospital of Xian jiaotong university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
First Affiliated Hospital of Xian Jiaotong University
Xi'an, Shaanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XJTU1AF2022LSL-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.